Abstract
Nearly one third of patients with newly diagnosed NSCLC is presented at locally advanced stage. Among these patients, standard treatment option for stage IIIA-N2 subgroup is still under discussion with controversies. We hypothesize that immune checkpoint inhibitor consolidation therapy could have an additional role in prolongation of the disease-free survival (DFS) for stage IIIA-N2 NSCLC treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have